WEST POINT PHARMA ADDING FIVE NON-MERCK PRODUCTS TO GENERIC LINE
WEST POINT PHARMA ADDING FIVE NON-MERCK PRODUCTS TO GENERIC LINE marketed by the Merck generic drug subsidiary, the company announced April 27. West Point is adding generic versions of Upjohn's Xanax (alprazolam), DuPont-Merck's Sinemet (carbidopa/levodopa), Parke-Davis' Lopid (gemfibrozil), Wyeth- Ayerst's Orudis (ketoprofen) and Syntex' Naprosyn (naproxen) in 14 different formulations. The drugs are being manufactured by other generic manufacturers under the West Point Pharma label.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth